Summarized by Masters of Longevity from Longevity Docs News.
Korea's regulator cleared upadacitinib for severe alopecia areata and vitiligo.
Key Takeaways
- South Korea approved upadacitinib for patients aged 12 and older.
- The label also added non-segmental vitiligo as an approved indication.
- Approval is based on trials with limited older-patient representation.
